Form 8-K - Current report:
SEC Accession No. 0001193125-25-315918
Filing Date
2025-12-11
Accepted
2025-12-11 16:06:08
Documents
12
Period of Report
2025-12-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evmn-20251211.htm   iXBRL 8-K 52036
2 EX-99.1 evmn-ex99_1.htm EX-99.1 199388
3 GRAPHIC img108483603_0.jpg GRAPHIC 645024
  Complete submission text file 0001193125-25-315918.txt   1266953

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evmn-20251211.xsd EX-101.SCH 33245
14 EXTRACTED XBRL INSTANCE DOCUMENT evmn-20251211_htm.xml XML 4877
Mailing Address 1841 PAGE MILL RD PALO ALTO CA 94304
Business Address 1841 PAGE MILL RD PALO ALTO CA 94304 (650) 223-7745
Evommune, Inc. (Filer) CIK: 0002044725 (see all company filings)

EIN.: 850742575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42938 | Film No.: 251565026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)